Cited by 84Virus-based gene therapy researchSARS-CoV-2 and COVID-19 ResearchVirology and Viral Diseases

Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20

Open access
McCraw, Dustin M., O’Donnell, Jason K., Taylor, Kenneth A., Stagg, Scott M., Chapman, Michael S.·2012·Virology

Abstract

The use of adeno-associated virus (AAV) as a gene therapy vector is limited by the host neutralizing immune response. The cryo-electron microscopy (EM) structure at 8.5Å resolution is determined for a complex of AAV-2 with the Fab' fragment of monoclonal antibody (MAb) A20, the most extensively characterized AAV MAb. The binding footprint is determined through fitting the cryo-EM reconstruction with a homology model following sequencing of the variable domain, and provides a structural basis for integrating diverse prior epitope mappings. The footprint extends from the previously implicated plateau to the side of the spike, and into the conserved canyon, covering a larger area than anticipated. Comparison with structures of binding and non-binding serotypes indicates that recognition depends on a combination of subtle serotype-specific features. Separation of the neutralizing epitope from the heparan sulfate cell attachment site encourages attempts to develop immune-resistant vectors that can still bind to target cells.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.virol.2012.05.004

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A20's epitope runs from the 2/5-fold wall toward the 5-fold axes and does not share residues with the peptide.

    “While the A20 epitope is positioned from the 2/5-fold wall towards the 5-fold axes and shares no residues with the peptide (McCraw et al., 2012), the C37-B epitope is significantly overlapped by the position of the inserted peptide (Fig. 8B).”

    From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as McCraw et al., 2012

    The Results and Discussion sections on the binding site and epitope place A20’s footprint across the plateau, wall, and canyon, supporting its general location. They do not establish that it extends toward the fivefold axes or compare its residues with the specific inserted peptide in the citing sentence; the paper discusses other peptide-insertion sites instead. Page numbers were not available in our copy. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
McCraw, D. M., O’Donnell, J. K., Taylor, K. A., Stagg, S. M., & Chapman, M. S.
Affiliations
  • Oregon Health & Science University (US)
  • Florida State University (US)
Corresponding author
Chapman, Michael S.
Venue
Virology
Publisher
Elsevier BV
Published
2012-09
Volume
431
Issue
1-2
Pages
40-49
ISSN
0042-6822 (ISSN-L)
OpenAlex
W2054723576
Cited by
84
References
76
Citations by year
2025: 5 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 6 · 2020: 8 · 2019: 7 · 2018: 8 · 2017: 4 · 2016: 8 · 2015: 8 · 2014: 6 · 2013: 8 · 2012: 2
FWCI
4.63
Type
journal article
Language
en
Open access
Locations
  • Virology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (R01GM66875, R01GM78538)
  • Office of Naval Research (N000141010082)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Keywords
adeno-associated virus type 2, AAV2, Fab fragment, virus-antibody complexes, capsid structure, neutralizing epitopes, heparan sulfate binding, gene therapy vectors, immune resistance, epitope mapping
MeSH terms
Dependovirus, Amino Acid Sequence, Antibodies, Monoclonal, Antibodies, Viral, Humans, Immunoglobulin Fab Fragments, Molecular Sequence Data, Molecular Structure, Epitope Mapping, Cryoelectron Microscopy, Protein Structure, Quaternary, Macromolecular Substances

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review